News & Updates

Type 2 diabetes (T2D) patients with COVID-19 who have elevated acute-to-chronic (A/C) glycaemic ratio are at increased risk of adverse outcomes, including in-hospital mortality, intensive care unit (ICU) admission, and mechanical ventilation, a study has found.

Vaccines against the coronavirus disease 2019 (COVID-19) induce weaker and more transient immune responses in liver transplant recipients, those with cirrhosis, or those with chronic liver disease (CLD), according to a study presented at The Liver Meeting Digital Experience 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).

Liver injury is not uncommon among patients with vaccine breakthrough COVID-19, indicating the importance of monitoring liver injury enzymes, according to a study presented at The Liver Meeting 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).

Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.

Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.

Burnout is experienced by nearly half (~40 percent) of hepatology providers during the COVID-19 pandemic, as shown by the negative impact of emotional well-being, including work fulfilment and satisfaction, according to a study.

New research suggests that COVID toe – a form of COVID-19–associated pernio or chilblains – may be a side effect of the immune system's response to fighting off the virus.